Key Details
Price
$1.44Annual ROE
-100.48%Beta
2.25Events Calendar
Next earnings date:
Mar 7, 2025Recent quarterly earnings:
Nov 8, 2024Recent annual earnings:
Mar 7, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IGM Biosciences, Inc. ("IGM Biosciences, Inc.") (NASDAQ:IGMS) concerning possible violations of federal securities laws. IGM issued a press release on January 9, 2025, "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases.
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago.
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
IGM Biosciences (IGMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $1.43 per share a year ago.
IGM Biosciences (IGMS) has the perfect mix of factors that could lead to better-than-expected earnings in its upcoming report. Be sure to have the key expectations in mind.
IGM Biosciences (IGMS) has been upgraded to a Zacks Rank #2 (Buy), indicating increased confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.19 per share a year ago.
The average of price targets set by Wall Street analysts indicates a potential upside of 63.1% in IGM Biosciences, Inc. (IGMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The consensus price target hints at a 35.1% upside potential for IGM Biosciences, Inc. (IGMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FAQ
- What is the ticker symbol for IGM Biosciences?
- Does IGM Biosciences pay dividends?
- What sector is IGM Biosciences in?
- What industry is IGM Biosciences in?
- What country is IGM Biosciences based in?
- When did IGM Biosciences go public?
- Is IGM Biosciences in the S&P 500?
- Is IGM Biosciences in the NASDAQ 100?
- Is IGM Biosciences in the Dow Jones?
- When was IGM Biosciences's last earnings report?
- When does IGM Biosciences report earnings?
- Should I buy IGM Biosciences stock now?